

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Lawrence GREENFIELD et al.)	Group Art Unit: 1637
)	
Application No.: 10/800,137)	Examiner: J. RILEY
)	
Filed: March 11, 2004)	
)	Confirmation No.: 6944
For: COMPOSITIONS, METHODS, AND)	
KITS FOR ISOLATING NUCLEIC)	
ACIDS USING SURFACTANTS AND)	
PROTEASES)	

Mail Stop Issue Fee

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents listed on the attached IDS Form PTO/SB/08. This Information Disclosure Statement is being filed after a Notice of Allowance but before payment of the issue fee and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e).

Each document listed on the attached IDS Form PTO/SB/08 was first cited in a communication from the European Patent Office in a counterpart foreign application, and this Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

In lieu of a statement of relevance or translation of the non-English documents, an Official Communication from the European Patent Office in a corresponding application citing and discussing those documents is attached. Applicants note that WO 01/10554 is incorrectly identified as WO 01/19554 in the Communication. Applicants also note that document EP 1018549, discussed in the Communication, was previously submitted in this application and considered by the Examiner.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please
charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 1, 2007

By: _____


Jennifer L. Davis
Reg. No. 54,632
Customer No. 22,852

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/800,137
Filing Date	March 11, 2004
First Named Inventor	GREENFIELD, Lawrence
Art Unit	1637
Examiner Name	RILEY, Jezia
Attorney Docket Number	07414.0022-02000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 01/10554 A2	02-15-2001	BILATEC GESELLSCHAFT ZUR ENTWICK-LUNG BIOTECHNOLOGISCHER SYSTEME MBH		No
		EP 1044984 A2	10-18-2000	GSF- FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT, GMBH		No

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Communication pursuant to Article 96(2) EPC mailed March 21, 2007, in European Patent Application No. 01 274 041.1 (5 pages).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.